Jennison Associates LLC Has $56.34 Million Stock Holdings in Boston Scientific Corporation $BSX

Jennison Associates LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 83.6% during the first quarter, Holdings Channel reports. The institutional investor owned 897,775 shares of the medical equipment provider’s stock after selling 4,570,520 shares during the quarter. Jennison Associates LLC’s holdings in Boston Scientific were worth $56,335,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. Norges Bank acquired a new position in shares of Boston Scientific during the fourth quarter valued at $2,199,395,000. Assenagon Asset Management S.A. increased its position in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after purchasing an additional 5,751,760 shares during the period. Maverick Capital Ltd. acquired a new stake in Boston Scientific in the fourth quarter worth about $280,735,000. Farallon Capital Management LLC raised its holdings in Boston Scientific by 56.7% during the 4th quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after purchasing an additional 2,693,007 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Boston Scientific by 31.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock worth $1,052,247,000 after purchasing an additional 2,668,230 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 9,800 shares of company stock worth $554,012 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 0.2%

Shares of NYSE BSX opened at $43.95 on Monday. The stock has a market cap of $65.33 billion, a P/E ratio of 18.39, a P/E/G ratio of 0.84 and a beta of 0.58. The firm has a 50 day moving average price of $48.18 and a 200 day moving average price of $65.66. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts expect that Boston Scientific Corporation will post 3.35 EPS for the current year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Leerink Partners reduced their target price on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research note on Thursday, May 28th. Mizuho dropped their price target on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday. Wells Fargo & Company restated an “equal weight” rating and issued a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research note on Thursday, April 23rd. Finally, Jefferies Financial Group lowered their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $79.84.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.